newsfilter
← Latest News
GlobeNewswire·

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)

FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. ("Cellectar") (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the